Literature DB >> 17204939

Expression of Nrf2 in neurodegenerative diseases.

Chenere P Ramsey1, Charles A Glass, Marshall B Montgomery, Kathryn A Lindl, Gillian P Ritson, Luis A Chia, Ronald L Hamilton, Charleen T Chu, Kelly L Jordan-Sciutto.   

Abstract

In response to oxidative stress, the nuclear factor E2-related factor 2 (Nrf2) transcription factor translocates from the cytoplasm into the nucleus and transactivates expression of genes with antioxidant activity. Despite this cellular mechanism, oxidative damage is abundant in Alzheimer and Parkinson disease (AD and PD). To investigate mechanisms by which Nrf2 activity may be aberrant or insufficient in neurodegenerative conditions, we assessed Nrf2 localization in affected brain regions of AD, Lewy body variant of AD (LBVAD), and PD. By immunohistochemistry, Nrf2 is expressed in both the nucleus and the cytoplasm of neurons in normal hippocampi with predominant expression in the nucleus. In AD and LBVAD, Nrf2 was predominantly cytoplasmic in hippocampal neurons and was not a major component of beta amyloid plaques or neurofibrillary tangles. By immunoblotting, we observed a significant decrease in nuclear Nrf2 levels in AD cases. In contrast, Nrf2 was strongly nuclear in PD nigral neurons but cytoplasmic in substantia nigra of normal, AD, and LBVAD cases. These findings suggest that Nrf2-mediated transcription is not induced in neurons in AD despite the presence of oxidative stress. In PD, nuclear localization of Nrf2 is strongly induced, but this response may be insufficient to protect neurons from degeneration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204939      PMCID: PMC2253896          DOI: 10.1097/nen.0b013e31802d6da9

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  54 in total

1.  Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival.

Authors:  Sara B Cullinan; Donna Zhang; Mark Hannink; Edward Arvisais; Randal J Kaufman; J Alan Diehl
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm.

Authors:  Laurie M Zipper; R Timothy Mulcahy
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

3.  Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans.

Authors:  Rudy J Castellani; George Perry; Sandra L Siedlak; Akihiko Nunomura; Shun Shimohama; Jing Zhang; Thomas Montine; Lawrence M Sayre; Mark A Smith
Journal:  Neurosci Lett       Date:  2002-02-08       Impact factor: 3.046

4.  Cell cycle proteins exhibit altered expression patterns in lentiviral-associated encephalitis.

Authors:  Kelly L Jordan-Sciutto; Guoji Wang; Michael Murphey-Corb; Clayton A Wiley
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

Review 5.  Mitochondria, oxidative damage, and inflammation in Parkinson's disease.

Authors:  M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

Review 6.  Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists.

Authors:  D Allan Butterfield; Sue Griffin; Gerald Munch; Giulio Maria Pasinetti
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

7.  Dietary intake of antioxidants and risk of Alzheimer disease.

Authors:  Marianne J Engelhart; Mirjam I Geerlings; Annemieke Ruitenberg; John C van Swieten; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler
Journal:  JAMA       Date:  2002-06-26       Impact factor: 56.272

8.  Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress.

Authors:  Keon Wook Kang; Seung Jin Lee; Jeong Weon Park; Sang Geon Kim
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

9.  Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants.

Authors:  Albena T Dinkova-Kostova; W David Holtzclaw; Robert N Cole; Ken Itoh; Nobunao Wakabayashi; Yasutake Katoh; Masayuki Yamamoto; Paul Talalay
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-22       Impact factor: 11.205

Review 10.  'Unfolding' pathways in neurodegenerative disease.

Authors:  Mark S Forman; Virginia M-Y Lee; John Q Trojanowski
Journal:  Trends Neurosci       Date:  2003-08       Impact factor: 13.837

View more
  241 in total

1.  CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Authors:  David A Loeffler; Lynnae M Smith; Mary P Coffey; Jan O Aasly; Peter A LeWitt
Journal:  J Neural Transm (Vienna)       Date:  2015-11-03       Impact factor: 3.575

Review 2.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

3.  Neuroprotective Effects of Apocynin and Galantamine During the Chronic Administration of Scopolamine in an Alzheimer's Disease Model.

Authors:  Eliezer Joseph; Daniel Miguel Ángel Villalobos-Acosta; Mónica Adriana Torres-Ramos; Eunice Dalet Farfán-García; Modesto Gómez-López; Ángel Miliar-García; Manuel Jonathan Fragoso-Vázquez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  J Mol Neurosci       Date:  2019-11-25       Impact factor: 3.444

Review 4.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 5.  The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.

Authors:  Prashant Deshmukh; Sruthi Unni; Gopinatha Krishnappa; Balasundaram Padmanabhan
Journal:  Biophys Rev       Date:  2016-12-06

6.  Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease.

Authors:  Yifeng Du; Michael C Wooten; Marla Gearing; Marie W Wooten
Journal:  Free Radic Biol Med       Date:  2008-11-21       Impact factor: 7.376

7.  Mitigation of ROS insults by Streptomyces secondary metabolites in primary cortical neurons.

Authors:  Marta Leirós; Eva Alonso; Jon A Sanchez; Mostafa E Rateb; Rainer Ebel; Wael E Houssen; Marcel Jaspars; Amparo Alfonso; Luis M Botana
Journal:  ACS Chem Neurosci       Date:  2013-11-19       Impact factor: 4.418

Review 8.  P62/SQSTM1 at the interface of aging, autophagy, and disease.

Authors:  Alessandro Bitto; Chad A Lerner; Timothy Nacarelli; Elizabeth Crowe; Claudio Torres; Christian Sell
Journal:  Age (Dordr)       Date:  2014-02-21

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Neuroprotective Effects of Kinetin Against Glutamate-Induced Oxidative Cytotoxicity in HT22 Cells: Involvement of Nrf2 and Heme Oxygenase-1.

Authors:  Yunpeng Wei; Dan Liu; Yin Zheng; Chaoshuang Hao; Honglian Li; Wuqing Ouyang
Journal:  Neurotox Res       Date:  2017-09-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.